Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	103631
Country	China

Received	2024-11-26 06:35
Peer-Review Started	2024-11-26 06:35
To Make the First Decision
Return for Revision	2024-12-12 07:23
Revised	2024-12-25 08:32
Second Decision	2025-02-07 02:36
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-02-07 06:11
Articles in Press	2025-02-07 06:11
Publication Fee Transferred	2025-01-06 06:19
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-03-07 07:49
Publish the Manuscript Online	2025-03-25 16:18

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Retrospective Study
Article Title	Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Lu-Wen Liang, Rong-Hong Luo, Zhi-Li Huang and Li-Na Tang
ORCID	Author(s) ORCID Number Rong-Hong Luo http://orcid.org/0009-0007-0396-3864
Funding Agency and Grant Number
Corresponding Author	Rong-Hong Luo, Professor, Department Of Infectious Diseases, The Third Affiliated Hospital of Chongqing Medical University, No. 1 Shuanghu Branch Road, Yubei District, Chongqing 401120, China. loudiudiu2024@163.com
Key Words	Nivolumab; Cabozantinib; Hepatocellular carcinoma; Tumor markers; Immune function
Core Tip	The combination therapy of cabozantinib and nivolumab in advanced hepatocellular carcinoma can upregulate T lymphocyte levels, reduce tumor marker levels, effectively prolong survival time, and has better efficacy than simple control treatment, with good safety.
Publish Date	2025-03-25 16:18
Citation	<p>Liang LW, Luo RH, Huang ZL, Tang LN. Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma. <i>World J Gastrointest Oncol</i> 2025; 17(4): 103631</p>
URL	https://www.wjgnet.com/1948-5204/full/v17/i4/103631.htm
DOI	https://dx.doi.org/10.4251/wjgo.v17.i4.103631

Full Article (PDF)	WJGO-17-103631-with-cover.pdf
Manuscript File	103631_Auto_Edited_054942.docx
Answering Reviewers	103631-answering-reviewers.pdf
Audio Core Tip	103631-audio.mp3
Biostatistics Review Certificate	103631-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	103631-conflict-of-interest-statement.pdf
Copyright License Agreement	103631-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	103631-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	103631-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	103631-non-native-speakers.pdf
Peer-review Report	103631-peer-reviews.pdf
Scientific Misconduct Check	103631-scientific-misconduct-check.png
Scientific Editor Work List	103631-scientific-editor-work-list.pdf
CrossCheck Report	103631-crosscheck-report.png
CrossCheck Report	103631-crosscheck-report.pdf